The trademark application was filed by D3 Bio (Wuxi) Co., Ltd., a corporation established under the laws of the People's Republic of China (the "Applicant"). The application was published for oppositions on September 29, 2021, and it was registered by office on January 6, 2022 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 42 with following description of goods:
Drug evaluation
Pharmaceutical research
Development services of drugs
Research services of drugs
Cancer research for medical purposes
Biological research
Clinical trials
Medical research
Research and development of antibodies
Development of pharmaceutical preparations and pharmaceuticals.